<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132015</url>
  </required_header>
  <id_info>
    <org_study_id>060076</org_study_id>
    <secondary_id>06-C-0076</secondary_id>
    <secondary_id>NCI-6454</secondary_id>
    <secondary_id>NCI-P6175</secondary_id>
    <secondary_id>CDR0000438778</secondary_id>
    <nct_id>NCT00132015</nct_id>
    <nct_alias>NCT00285311</nct_alias>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis</brief_title>
  <official_title>A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin&#xD;
      (17-AAG), work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well 17-AAG works in treating patients with&#xD;
      systemic mastocytosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), in terms of&#xD;
           decreases in the number of mast cells in the bone marrow and in serum tryptase levels,&#xD;
           in patients with systemic mastocytosis.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this drug.&#xD;
&#xD;
        -  Determine hematological and non-hematological toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days&#xD;
      1, 4, 8, and 11. Treatment repeats every 21 days for at least 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients achieving a complete response (CR)&#xD;
      receive at least 2 additional courses beyond CR. Patients achieving a partial response&#xD;
      receive at least 4 additional courses beyond their maximum response. Selected patients may&#xD;
      receive additional courses of therapy beyond the protocol guidelines at the discretion of the&#xD;
      principal investigator.&#xD;
&#xD;
      Quality of life is assessed at baseline and before each treatment course.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within&#xD;
      approximately 10-18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (complete and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the European Organization for Research of the Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at baseline and prior to each treatment course</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Nonneoplastic Condition</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed systemic mastocytosis&#xD;
&#xD;
               -  Objective evidence of disease, as defined by the following:&#xD;
&#xD;
                    -  Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
                    -  Recurrent mast cell mediator-release symptoms that impair the patient's&#xD;
                       quality of life&#xD;
&#xD;
                    -  Symptomatic hepatosplenomegaly&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Symptomatic bone disease&#xD;
&#xD;
                    -  Profound constitutional symptoms (e.g., fatigue, asthenia, flushing,&#xD;
                       hyperpyrexia, weight loss, myalgia, and arthralgia)&#xD;
&#xD;
                    -  Elevated serum tryptase level&#xD;
&#xD;
          -  Mast cell leukemia allowed&#xD;
&#xD;
          -  Mastocytosis associated with myeloproliferative disease (e.g., hypereosinophilic&#xD;
             syndrome or chronic myelomonocytic leukemia) allowed&#xD;
&#xD;
          -  Patients with eosinophilia (i.e., absolute eosinophil count ≥ 1,000/mm^3) must be&#xD;
             evaluated for the presence or absence of FIP1L1-PDGFRA mutation; if the mutation is&#xD;
             absent, the patient is eligible; if the mutation is present, the patient is eligible&#xD;
             provided disease is refractory to imatinib mesylate&#xD;
&#xD;
          -  Patients with indolent disease must have a serum tryptase level ≥ 50 ng/mL OR episodes&#xD;
             of anaphylaxis that occur with a frequency of &gt; 1 per month&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (&gt; 25,000/mm^3 for patients with organomegaly)&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3(&gt; 750/mm^3 for patients with organomegaly)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal (ULN) (&lt; 4 times ULN for patients with&#xD;
             hepatomegaly)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.4 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III-IV congestive heart failure&#xD;
&#xD;
          -  No history of myocardial infarction within the past year&#xD;
&#xD;
          -  No history of uncontrolled dysrhythmia&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No ischemic heart disease within the past 12 months&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
          -  No serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation&#xD;
             ≥ 3 beats in a row)&#xD;
&#xD;
          -  QTc interval &lt; 450 msec for males or 470 msec for females&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA&#xD;
&#xD;
          -  MUGA or echocardiogram normal&#xD;
&#xD;
          -  No prior history of cardiac toxicity after receiving anthracyclines (e.g., doxorubicin&#xD;
             hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or&#xD;
             carmustine)&#xD;
&#xD;
          -  No cardiac symptoms ≥ grade 2&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No symptomatic pulmonary disease requiring medication including any of the following:&#xD;
&#xD;
               -  Dyspnea on or off exertion&#xD;
&#xD;
               -  Paroxysmal nocturnal dyspnea&#xD;
&#xD;
               -  Requirement for oxygen&#xD;
&#xD;
               -  Significant pulmonary disease (e.g., chronic obstructive/restrictive pulmonary&#xD;
                  disease)&#xD;
&#xD;
          -  No home oxygen meeting the Medicare requirement&#xD;
&#xD;
          -  No compromised pulmonary status (i.e., DLCO ≤ 80%)&#xD;
&#xD;
          -  No prior history of pulmonary toxicity after receiving anthracyclines (e.g.,&#xD;
             doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride,&#xD;
             bleomycin, or carmustine)&#xD;
&#xD;
          -  No pulmonary symptoms ≥ grade 2&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No serious medical illness&#xD;
&#xD;
          -  No other non-malignant systemic disease&#xD;
&#xD;
          -  No history of serious allergic reaction to eggs&#xD;
&#xD;
          -  No other malignancy within the past 2 years except dermatological cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Steroids allowed provided tapering to the lowest level possible to treat&#xD;
             thrombocytopenia, diarrhea, or malabsorption symptoms of systemic mastocytosis&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiation that included the heart in the field (e.g., mantle) or chest&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior tyrosine kinase inhibitors&#xD;
&#xD;
          -  No concurrent complimentary or alternative medications* including, but not limited to,&#xD;
             the following:&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Milk thistle&#xD;
&#xD;
               -  Kava kava&#xD;
&#xD;
               -  Mistletoe extract&#xD;
&#xD;
          -  No concurrent agents that cause QTc prolongation&#xD;
&#xD;
          -  No concurrent antiarrhythmic therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy NOTE: *Unless approved by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio T. Fojo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2005</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>multicentric Castleman disease</keyword>
  <keyword>unicentric Castleman disease</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>hairy cell leukemia</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>adult Burkitt lymphoma</keyword>
  <keyword>adult diffuse large cell lymphoma</keyword>
  <keyword>adult diffuse mixed cell lymphoma</keyword>
  <keyword>adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>adult immunoblastic large cell lymphoma</keyword>
  <keyword>adult lymphoblastic lymphoma</keyword>
  <keyword>grade 1 follicular lymphoma</keyword>
  <keyword>grade 2 follicular lymphoma</keyword>
  <keyword>grade 3 follicular lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>marginal zone lymphoma</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

